B. Barrow - Concepedia

Author

B. Barrow

Oxford Centre for Diabetes, Endocrinology and Metabolism

Also Known As

B Barrow, B. A. Barrow, B. Barrow, B.A Barrow, B.A. Barrow, Beryl A Barrow, Beryl A. Barrow, Beryl Barrow, F. Martín

Publications

7.5K

Citations

H-Index

Concepts

All Affiliations

Oxford Centre for Diabetes, Endocrinology and Metabolism John Radcliffe Hospital University of Oxford Churchill Hospital Centre for Human Genetics

About

B. Barrow is an author at Oxford Centre for Diabetes, Endocrinology and Metabolism specializing in diabetes, medicine, and genetic epidemiology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	2.1K
2	Public Health	3	3	346
3	Health Sciences	2	2	283
4	Natural Sciences	1	1	10
5	Biochemistry	1	1	10

B. Barrow

Publications

7.4K

Citations

H-Index

Page 1

	Year	Citations
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 M R Stearne, S L Palmer, M S Hammersley,	1998	4.8K
Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39 M R Stearne, S L Palmer, M S Hammersley, HypertensionPharmacotherapyBlood PressureMicrovascular DysfunctionAtherosclerosis	1998	1.4K
Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40 M R Stearne, S L Palmer, M S Hammersley, HypertensionCost Effectiveness RatiosCost Effectiveness AnalysisBlood PressureNon-pharmacological Intervention	1998	303
Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM Jonathan Rachman, B. Barrow, J Lévy, Diabetologia Metabolic SyndromeInsulin ManagementDiabetesPhysiologyContinuous Administration	1997	268
Normalization of Insulin Responses to Glucose by Overnight Infusion of Glucagon-Like Peptide 1 (7–36) Amide in Patients With NIDDM Jonathan Rachman, Fiona M. Gribble, B. Barrow, Diabetes	1996	116
High prevalence of a missense mutation of the glucokinase gene in gestational diabetic patients due to a founder-effect in a local population P. J. Saker, Andrew T. Hattersley, B. Barrow, Diabetologia Glucokinase GeneGeneticsDiabetesGenetic EpidemiologyLocal Population	1996	65
Clinical Characteristics of Subjects with a Missense Mutation in Glucokinase R. Page, J Lévy, B. Barrow, Diabetic Medicine	1995	56
Safety of antipsychotics in people with intellectual disability Valeria Frighi, Matthew T. Stephenson, Alireza Morovat, The British Journal of Psychiatry	2011	55
UKPDS 21: Low Prevalence of the Mitochondrial Transfer RNA gene (tRNALeu(UUR)) Mutation at Position 3243bp in UK Caucasian Type 2 Diabetic Patients P. J. Saker, Andrew T. Hattersley, B. Barrow, Diabetic Medicine	1997	51
Identification of a Novel β-Cell Glucokinase (<i>GCK</i>) Promoter Mutation (−71G&gt;C) That Modulates<i>GCK</i>Gene Expression Through Loss of Allele-Specific Sp1 Binding Causing Mild Fasting Hyperglycemia in Humans Daniela Gašperíková, Nicolas D. Tribble, Juraj Staník, Diabetes	2009	41

Page 1